Products Re-Priced Due to Market Expansion Should Be Eligible for New Drug Premium to Promote Innovation: FPMAJ

The Federation of Pharmaceutical Manufacturers’ Associations of Japan’s (FPMAJ) NHI Drug Price Study Committee announced a report on June 8 that evaluates the FY2012 drug price revision and recommends issues for future discussion. Among other things, the report criticizes the...read more